A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
about
The clinical relevance of omega-3 fatty acids in the management of hypertriglyceridemiaPrescription omega-3 fatty acid products: considerations for patients with diabetes mellitusOmega-3 carboxylic acids monotherapy and combination with statins in the management of dyslipidemiaOverview of prescription omega-3 fatty acid products for hypertriglyceridemiaA Comparative Overview of Prescription Omega-3 Fatty Acid ProductsUpdate on the management of severe hypertriglyceridemia--focus on free fatty acid forms of omega-3.Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trialOmega-3 Fatty Acid Formulations in Cardiovascular Disease: Dietary Supplements are Not Substitutes for Prescription Products.Switching from EPA + DHA (Omega-3-acid Ethyl Esters) to High-Purity EPA (Icosapent Ethyl) in a Statin-Treated Patient with Persistent Dyslipidemia and High Cardiovascular Risk: A Case Study.Effect of n-3 Polyunsaturated Fatty Acids on Regression of Coronary Atherosclerosis in Statin Treated Patients Undergoing Percutaneous Coronary Intervention.Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II studyPolyunsaturated fatty acyl-coenzyme As are inhibitors of cholesterol biosynthesis in zebrafish and mice.Overview of omega-3 Fatty Acid therapiesA Review of Clinical Practice Guidelines for the Management of Hypertriglyceridemia: A Focus on High Dose Omega-3 Fatty Acids.Multiple differences between patients who initiate fish oil supplementation post-myocardial infarction and those who do not: the TRIUMPH Study.Nanoparticulate carrier system: a novel treatment approach for hyperlipidemia.Addition of omega-3 carboxylic acids to statin therapy in patients with persistent hypertriglyceridemia.N-3 fatty acids for prevention of cardiovascular disease.ω-3 carboxylic acids for hypertriglyceridemia.Current Treatment of Dyslipidemia: Evolving Roles of Non-Statin and Newer Drugs.Bioactive compounds as an alternative for drug co-therapy: Overcoming challenges in cardiovascular disease prevention.Omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid and their mechanisms of action on apolipoprotein B-containing lipoproteins in humans: a review.Lipid lowering nutraceuticals in clinical practice: position paper from an International Lipid Expert Panel.Changes in Bioavailability of Omega-3 (DHA) through Alpha-Tocopheryl Phosphate Mixture (TPM) after Oral Administration in Rats.Review of Cardiometabolic Effects of Prescription Omega-3 Fatty Acids.Comparing the Impact of Prescription Omega-3 Fatty Acid Products on Low-Density Lipoprotein Cholesterol.Omega-3-carboxylic acids provide efficacious anti-inflammatory activity in models of crystal-mediated inflammation.Challenges in the treatment of hypertriglyceridemia: glass half empty or half full?PPAR Agonists and Metabolic Syndrome: An Established Role?
P2860
Q26738554-6598EDC7-F875-4783-B235-463EE6AD1977Q26752919-A5B48D92-2EA4-4AE8-9297-B8C14ADBDB5BQ28076399-F5A5D7F0-EE9C-4474-A465-629417338934Q28251391-91BB0DBE-2A78-49A7-998E-1326948F5157Q28972330-1F6CCD4D-993B-4E1A-B703-15CD17932C1CQ35460381-9C0FD6B2-FB6A-480B-AB88-787941522548Q36019971-BDD358A8-E5DC-494E-9875-34AAB3A535B2Q37099337-1EEE4235-01AB-428B-973B-FB3D4FB150D9Q37118744-902FD421-6DF1-4692-8BF0-32A6237B3572Q37136513-E342411C-7D1F-4B81-B8B9-A0FC43E32B0AQ37225366-7B7098DC-5D75-436A-96FE-C1EAC225F6A3Q37287426-3DD02BFD-762B-459E-B720-34CCCFC1C3DFQ37419411-6AB7A43A-A581-47A9-AD26-EF57E5CDA4B6Q37672465-0A053F05-BDC9-4211-8D8D-34DEE965A4CBQ37720139-0CDFC4BE-2D79-4A04-9A88-A1D9A94E733EQ38218145-7C393739-3A8B-4D13-9AC1-6C328D3CFAB8Q38236677-356A4580-03B6-476E-B800-880AB1BDA116Q38248569-62E0C7EB-24F3-4E9C-A15E-20664A66BE65Q38283976-9415CE58-153E-4247-8D3A-91715C241942Q38546242-F14CFD35-A6A9-40B6-9BD0-D9940EF3E384Q39004398-4709CA97-3A7A-49D7-962A-F3132476837CQ41363466-A2FF6A8A-5278-4998-A852-F03CB1C32311Q41549715-ACE7D594-436C-47E3-A5A9-1E6D275E1277Q41997405-D142102D-B25D-4682-B0B6-BDECCEBA3400Q47633216-9D6A5CB3-F2CE-44F5-8DD4-D02429284F34Q47696256-C692C37E-84D2-489F-9161-D21E588B6A96Q49910318-672E23EF-EDE7-49E7-8DB6-D27DD641386FQ51301866-06982EC7-504E-44CA-8E77-3E9EFC28B5E8Q54936265-D58E2BDA-4F81-4E11-B269-C5E302F449E6
P2860
A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@en
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@nl
type
label
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@en
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@nl
prefLabel
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@en
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@nl
P2093
P921
P1476
A highly bioavailable omega-3 ...... yceridemia (the ESPRIT trial).
@en
P2093
Danielle Curcio
David G Orloff
Douglas Kling
Eli M Roth
Kevin C Maki
Michael H Davidson
Richard L Dunbar
Stephen J Nicholls
P304
1400-11.e1-3
P356
10.1016/J.CLINTHERA.2013.07.420
P577
2013-08-30T00:00:00Z